YEAR EVENTS 1976 - The Company was incorporated in December, in the name of J.B. Mody Chemicals and Pharmaceuticals Ltd. Later the name was changed to J.B. Chemical and Pharmaceuticals Ltd. and a fresh Certificate of Incorporation upon change of name was issued on 21st August, 1985 by the Registrar of Companies, Maharashtra at Mumbai. - J.B. Chemicals and Pharmaceuticals Ltd. is the flagship of the `Unique' group of companies. The Company was founded by Mr. J.B. Mody along with his two brothers, Mr. D.B. Mody and Mr. S.B. Mody. It is engaged in the business of manufacturing bulk drugs, intermediates, formulations, ayurvedic and herbal preparations. - The Company's manufacturing facilities are situated at Thane, Belapur, Ankleshwar, Panoli and Daman. 1992 - The Company has commisioned its Soft Gelatine Capsules project at Panoli in Gujarat. 1993 - The Company issued 20,17,500 No. of Equity Shares of Rs. 10/- each as fully paid up bonus shares to the shareholders in the ratio of one bonus share for every two Equity Shares held by capitalising a sum of Rs. 2,01,75,000/- from the Free Reserves of the Company. 1994 - The company allotted 20,17,500 No. of equity shares as fully paid bonus shares on December 1, 1993 by capitalisation of reserves to the tune of Rs. 201.75 lakhs. 1996 - The Company during the past year has introduced many new formulations in the local market. It has also increased its Bulk Drugs activity due to its R & D work and is able to increase its exports of Bulk Drug and formulations to various countries. 1998 - The company has launched a slew of new drugs including products for vaginitis, gingivitis, periodontitis, pelvic inflammatory diseases and diarrhoea. Besides, it has also forged a technical collaboration with Fresenins GmbH, Austria for marketing their specialty products for chronic constipation, prehepatic and hepatic coma. 1999 - J. B. Chemicals and Pharmaceutical Ltd is in talks with US consulting firms to help it enter the generic market for metronidazole and ranitidine in the US. 2000 - JB Chemicals and Pharmaceuticals is merging pharma divisions of two other companies - Unique Pharmaceutical Laboratories (UPL) and Ifiunik Pharmaceuticals (IPL) - into itself. 2002- JB Chemicals & Pharmaceuticals Ltd has informed that the following changes have taken place in the Directorship of the Company: 1 Dr S Agarwala has resigned as a Director w e f March 08, 2002 2 Mr Bansi S Mehta has resigned as alternate Director to Mr Vishnu D Patel w e f March 08, 2002 3 Dr S Agarwala has been appointed as Alternate Director to Mr Vishnu D Patel w e f March 08, 2002 4 Mr Bansi S Mehta has been appointed as Director in casual vacancy caused due to resignation of Dr S Agarwala w e f March 08, 2002. -J. B. Chemicals join hands with Neotherapeutics of USA. -JB Chem & Pharma and Neotherapeutics form JV to manage US Clinical Development, Regulatory Approvals and Marketing for JB Products. -: JB Chemicals & Pharmaceuticals has closed down its wholly owned subsidiary in Mauritius, which was floated in a bid to enhance its exports to European and other countries. 2003 -JBCPL files its first Abbreviated New Drug Application with the US Food and Drug Administration. -JBCPL becomes the first Indian Company to receive permission from drugs controllers General of India to market Rantac CD formulations. -JB Chem team up with White Chemicals for European generics Markets. -JB Chem appoints Dr Rajen Shah as the whole time Director on the board of the company. -The Company launches two new therapeutic products Cefjoy and Zudo for treatment of infections and health improvement. -Jb Chemicals & Pharmaceuticals Ltd. has informed that the equity shares of the company have been delisted by ASE w.e.f December 8, 2003. 2004 -JB Chem bags US FDA approval for Panoli drug unit, Gujarat - Bags final approval from the United States Food and Drug Administration (US FDA), to manufacture and market ciprofloxacin tablets 250 mg, 500 mg and 750 mg in the US market. -JB Chemicals launches Magnilek, a MRI Contrast media 2005 - TGA Australia approves JBCPL's tablet manufacturing facilities at Panoli, Gujarat, India. - JBCPL receives USFDA approval to market Fluconazole tablets in the US market. - JBCPL features in Forbes Asia Pacific 200 List for "Best under a Billion" for second year in a row. -Company has splits its Face value of Shares from Rs 10 to Rs 2 2006 - "J. B. Chemicals enters into Product Development Agreement with Taro Pharmaceutical Industries Ltd." - JB Chemicals & Pharmaceuticals Ltd has announced that the Company has launched a new speciality division christened "AUSTER" (means south wind that bring health and prosperity). - JB Chemicals announces a Licensing Agreement with Gilead Sciences Inc for Manufacturing and Distribution of a Generic Version 2007 - JBCPL's Annual Report for the year ended March 31, 2005 was awarded a merit certificate by the South Asian Federation of Accountants (SAFA), an apex body of SAARC, for the Best Presented Accounts for the year 2005 in the category of Hospitality, Health, Transport, Shipping, etc. - The Hon'ble High Court of Judicature of Bombay at Mumbai has sanctioned the Scheme of Amalgamation of Lekar Healthcare Ltd. with the Company. 2008 - JB Chemicals & Pharmaceuticals Ltd has informed that the Unique Pharmaceutical Laboratories (A Div of J B Chemicals & Pharmaceuticals Ltd) are to announce receiving one more international quality accreditation for their pharmaceutical manufacturing facility at Panoli, Gujarat. - Strategic investment in a company in South Africa called Biotech Laboratories. 2009 - JB Chem&Phrm - J.B. Chemicals receives US FDA approval for Diclofenace Sodium Tablets. 2010 - JB Chemicals - Board recommends dividend. - JB Chem&Phrm - J.B. Chemicals receives US FDA approval for Diclofenace Sodium Tablets. 2011 - Divested the OTC portfolio in Russia, Ukraine and CIS to J&J. - JB Chem&Phrm - J. B. Chemicals launches a New Domestic Division. -JB Chem&Phrm - J.B. Chemicals announces completion of its transaction of Sale of Russia-CIS OTC Business to Cilag GmbH Intern. - JB Chem&Phrm - J.B.Chemicals declares handsome onetime special dividend. 2012 - JB Chem&Phrm - Board recommends Dividend 2013 -J B Chemicals & Phar - Intimation of new ANDA approval 2014 -The company has appointed Mr. Devang R. Shah as an additional director of the Company. He is an independent director on the board. 2015 -JB Chem&Phrm manufactures specialty products that include various pharmaceutical dosage forms like tablets, injectable, creams and ointments, lozenges, herbal liquids and capsules. 2018 - JB Chem&Phrm. Successful US FDA inspection of API Manufacturing facility at Panoli, Gujarat. -JB Chem&Phrm got approval from US FDA for a New Drug Application (ANDA) for Midodrine Hydrochloride Tablets USP 2.5 mg, 5 mg. and 10 mg. (for treatment of orthostatic hypotension). 2020 -JB Chem&Phrm got approval from US FDA for a New Solid Oral dosage forms formulations manufacturing facility at Panoli, Gujarat. -JB Chem&Phrm got approval from US FDA for a New Drug Application (ANDA) for Carbamazepine Extended Release Tablets USP 100 mg, 200 mg and 400 mg. (for treatment of Epilepsy and Trigeminal Neuralgia). 2021 -JB Chemicals posted yet another strong quarter of growth to cap off its 2021 financial year, with broad revenue increases and a focus on `cost excellence' leading to increased profit margins. -JB Chemicals is a debt-free cash rich company, which can generate free cash flows of Rs 250cr annually with limited capex of Rs 100 crore. -JB Chemicals Launch of new dedicated division "RENOVA" to enter Nephrology segment in India. 2022 -J B Chemicals & Pharmaceuticals Acquisition of Brands and Related Assets from Sanzyme Private Limited. 2023 -The Company has splits its face value from Rs. 2/- to Rs. 1/-. -JB Chemicals & Pharmaceuticals has received approval from the US health regulator to market a generic product, used to treat mood disorders, in the American market. 2024 -The Company Launch of new dedicated division RENOVA to enter Nephrology segment in India. -The Company Informed US FDA has approved Company's Abbreviated New Drug Application for Carbamazepine Extended Release Tablets USP 100 mg, 200 mg and 400 mg. -The company BOD has approved purchase of Pharmaceutical Business Undertaking of Lekar Pharma Limited.